Volpara Health Technologies Ltd (ASX: VHT) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Volpara Health Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $221.29 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 251.46 million
Earnings per share -0.063
Dividend per share N/A
Year To Date Return -14.42%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Volpara Health Technologies Ltd (ASX: VHT)
Latest News

VHT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Volpara Health Technologies Ltd

Volpara Health Technologies Ltd is a New Zealand-based research, development and manufacturing company. The company operates through the sale of a single suite of medical device software products. The business of the company operates through three product categories that include Capital Sales, Software Maintenance Agreement, and Software as a Service. Geographically the company exports its products to Asia Pacific, Europe, Middle East, Africa, USA, and Canada regions. The company's product consists of breast imaging analytics platform that delivers real-time quality assurance and performance monitoring. Volpara Health Technologies sells its product under the name of VolparaDensity, VolparaDose, VolparaServer, and VolparaAnalytics.

VHT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
24 Jan 2022 $0.88 $-0.01 -1.12% 526,803 $0.89 $0.89 $0.87
21 Jan 2022 $0.89 $-0.03 -3.26% 327,771 $0.91 $0.92 $0.88
20 Jan 2022 $0.92 $0.01 1.10% 474,927 $0.91 $0.95 $0.91
19 Jan 2022 $0.91 $-0.03 -3.17% 505,140 $0.95 $0.95 $0.90
18 Jan 2022 $0.95 $-0.02 -2.08% 515,261 $0.95 $0.95 $0.92
17 Jan 2022 $0.96 $-0.01 -1.04% 181,554 $0.96 $0.98 $0.95
14 Jan 2022 $0.97 $-0.02 -2.03% 236,195 $0.99 $0.99 $0.96
13 Jan 2022 $0.99 $0.00 0.00% 162,259 $0.99 $1.00 $0.98
12 Jan 2022 $0.99 $-0.02 -2.00% 99,476 $1.00 $1.00 $0.98
11 Jan 2022 $1.00 $-0.01 -0.99% 303,239 $1.00 $1.00 $0.98
10 Jan 2022 $1.02 $0.00 0.00% 135,866 $1.02 $1.02 $0.99
07 Jan 2022 $1.02 $-0.01 -0.98% 95,638 $1.02 $1.02 $0.99
06 Jan 2022 $1.02 $0.01 0.99% 179,436 $1.01 $1.02 $1.00
05 Jan 2022 $1.01 $-0.03 -2.87% 132,238 $1.04 $1.04 $1.01
04 Jan 2022 $1.05 $0.00 0.00% 145,669 $1.04 $1.05 $1.03
31 Dec 2021 $1.04 $0.02 1.95% 55,716 $1.03 $1.04 $1.02
30 Dec 2021 $1.03 $-0.01 -0.97% 158,385 $1.04 $1.05 $1.01

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
18 Aug 2021 Roger Allen Issued 150 $199,500
Issue of options. Considered Trade Qty from value consideration as Qty was not reported in number acquired.
10 Jun 2021 Monica Saini Sell 100 $121,500
On-market trade.
01 Jun 2021 Monica Saini Exercise 180 $108,000
Exercise of options.
01 Jun 2021 Monica Saini Buy 180 $108,000
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr John Flower Diddams Non-Executive Director Oct 2015
Mr Diddams has knowledge and practical experience in the application of Australian corporations law, ASX Listing Rules, international accounting standards, and corporate governance principles. Over the past 30 years he has managed the processes to raise capital, perform due diligence, and seek ASX listing for a number of enterprises, including IPOs for a range of offerings. These include oil and gas interests, food and retail, a fine wool processing plant, an telephony product, a biotech company, an Internet advertising initiative, a dental device for snoring and sleep apnoea, an indoor skydiving company, the New Zealand developer of the Martin Jetpack, a healthy fast food chain, and Skydive the Beach Group Limited (now Experience Co Limited). He is a Non-Executive Director of Aroa Biosurgery Limited, a New Zealand based company that develops and markets proprietary soft tissue regenerative products, and Surf Lakes Holdings Limited, a Gold Coast based business with patented technology for recreational wave generation.
Mr Roger Allen Non-Executive DirectorNon-Executive Chairman Jun 2010
Mr Allen is a experienced entrepreneur and investor in early stage growth companies in Australia, New Zealand and internationally. In 1996 he cofounded Allen & Buckeridge, an early-stage venture capital fund with offices in Silicon Valley and Australia. He has served on two Prime Ministers Science and Technology Councils and Advisory Boards, and was Deputy Chairman of the Australian Governments Export Agency, Austrade, from 1990 to 1997. Previously an Adjunct Professor in the Business School of the University of Technology Sydney, he has also lectured at the School of Entrepreneurship at INSEAD. He has been awarded the two lifetime awards in the IT industry (CSIRO Tony Benson award and the Pearcey Medal for lifetime achievement)
Dr Ralph Highnam Chief Executive OfficerExecutive Director Feb 2009
Dr Highnam has been in the digital breast imaging field for over 30 years. His work as a research scientist in breast imaging technology at the University of Oxford led him to form first OXIVA Limited and then Mirada Solutions with Professor Sir John Mike Brady. Under his leadership Mirada became the number one provider of image registration and fusion tools before being acquired by CTI Molecular Imaging Inc. and later Siemens Medical Solutions USA, Inc. He consulted medical imaging companies which includes R2, Siemens, Hologic, and Dexela, as well as breast screening programs. During this time, he continued his academic research as part of an international circle of collaborators. He is the author of articles and, with Brady, the seminal book Mammographic Image Analysis. He provides the possible measurements of breast composition (breast density) in order to improve the health outcomes of women around the world. He was also named a Wellingtonian of the Year finalist.
Mr John Dimitrious Pavlidis Non-Executive Director Feb 2015
Mr Pavlidis has more than 30 years of medical device experience as a senior executive, CEO or company director in the areas of diagnostic imaging, women's health, image analysis and artificial intelligence, and cardiovascular therapies. Until recently, he served as the President and CEO of Vytronus, Inc., a venture backed startup using novel catheterbased ultrasound and robotics technology to treat atrial fibrillation, a cardiac arrhythmia. Prior to Vytronus, he was the President and CEO of Endoscopic Technologies, Inc., until it was acquired by AtriCure, Inc. in 2014. Since 2007, he has also served on the board of directors of several health technology companies, including U-systems, Inc., which pioneered automated breast ultrasound imaging as an adjunct to mammography for breast cancer screening and was acquired by GE Healthcare in 2012. Previously, he served as President and CEO of R2 Technology, Inc., computer assisted detection of breast cancer, until Hologic, Inc. acquired the company in 2006. Prior R2 Technology, he was president of the global Ultrasound business at Siemens Healthcare.
Mr Paul Reid Non-Executive DirectorNon-Executive Chairman Mar 2018
Mr Reid brings commercial experience gained across a range of technology/ Software as a Service (SaaS) businesses. He was the founding CEO and Chairman of Figured Limited, a fintech SaaS company that provides management accounting software to farmers in the United States, United Kingdom, Australia, and New Zealand. He is also currently CEO of Author-it Software Corporation, which provides documentation software for clinical, medical, and labelling information to life sciences companies in Europe and the United States. Other key directorship roles include Christchurch International Airport Limited and Comvita Limted. He held a number of key executive roles in businesses such as Air New Zealand, MetService, Carter Holt Harvey, and Ernst & Young.
Ms Karin Lindgren Non-Executive Director Jan 2020
Ms Lindgren has 35 years experience in health information technology as a senior technology executive and law firm partner. She has knowledge of data governance, data privacy, SaaS, and US healthcare, and has professional networks across the IT landscape. Her previous roles include General Counsel, Chief Compliance Officer & Chief Privacy Officer at the University HealthSystem Consortium, General Counsel & Chief Privacy Officer at ReedGroup, a data and informatics technology company. She served as a Senior VP, Legal Affairs, General Counsel, Corporate Secretary, Chief Compliance Officer, Chief Privacy Officer, and Chief Audit Executive at Availity, a revenue-cycle management, electronic data interchange platform, PaaS IT company that operates the real time information network in healthcare. She was a founding faculty member in the Health Informatics Master's Programs at both Northwestern University (Chicago), and University of Colorado (College of Nursing), and has taught in schools of medicine, law, and business at US universities. She is also a board member of private and non-profit organisations. She is Chair of the Risk Committee.
Ms Ann Custin Non-Executive Director Sep 2021
Ms Custin is an experienced senior healthcare general manager and finance executive with over 15 years' executive leadership experience from European and American healthcare companies, including Siemens Medical Solutions and Draeger Medical Systems. She has network of industry contacts from a career in healthcare across Europe, the Americas, and Asia. Her most recent executive role was with Siemens Healthineers, where she served as both CFO and board director of Siemens Medical Solutions. Prior to this Ann served as chief operating and financial officer of Scient'x and President & CEO of USA Draeger Medical Systems, Inc. Ann is also a Non-Executive Director of NASDAQ-listed Establishment Labs Holdings Inc., a medical technology company.
Mr Craig Hadfield Chief Financial OfficerJoint Company Secretary Mar 2017
Craig Hadfield Chief Financial OfficerJoint Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia 20,555,918 8.19%
Patagorang Pty Ltd 18,467,848 7.36%
Ralph Highnam And Kyc Trustees 16,213,561 6.46%
Citicorp Nominees Pty Limited 12,062,094 4.81%
Custodial Services Limited (Beneficiaries Holding A/C) 8,828,122 3.52%
Prof Sir Michael Brady 6,619,075 2.64%
Mr Marcus Sarner 5,980,404 2.38%
National Nominees Limited 4,327,085 1.72%
HSBC Custody Nominees (Australia) Limited 3,757,745 1.50%
Sir Martin Francis Wood 3,004,655 1.20%
Lady Kathleen Audrey Wood 3,004,654 1.20%
BNP Paribas Noms (Nz) Ltd (Drp) 2,881,734 1.15%
Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) 2,840,573 1.13%
BNP Paribas Nominees Pty Ltd Six Sis Ltd (Drp A/C) 2,198,322 0.88%
Prof Martin Yaffe 2,066,483 0.82%
Prof Nico Karssemeijer 1,806,806 0.72%
Sir Martin Gregory Smith 1,366,977 0.54%
Whitfield Investments Pty Ltd 1,030,767 0.41%
Pickard Capital Pty Ltd 1,029,106 0.41%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd (Drp A/C) 1,028,394 0.41%